Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Guggenheim Capital LLC

Guggenheim Capital LLC lowered its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 76.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,743 shares of the medical equipment provider's stock after selling 21,357 shares during the quarter. Guggenheim Capital LLC's holdings in Hologic were worth $486,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in HOLX. Aware Super Pty Ltd as trustee of Aware Super purchased a new position in Hologic during the 4th quarter valued at approximately $734,000. Canada Post Corp Registered Pension Plan purchased a new position in Hologic during the 4th quarter valued at approximately $234,000. Sterling Capital Management LLC grew its holdings in Hologic by 51.3% during the 4th quarter. Sterling Capital Management LLC now owns 14,099 shares of the medical equipment provider's stock valued at $1,016,000 after buying an additional 4,779 shares in the last quarter. Covestor Ltd grew its holdings in Hologic by 49.3% during the 4th quarter. Covestor Ltd now owns 1,033 shares of the medical equipment provider's stock valued at $75,000 after buying an additional 341 shares in the last quarter. Finally, Kennedy Capital Management LLC grew its holdings in Hologic by 13.0% during the 4th quarter. Kennedy Capital Management LLC now owns 64,846 shares of the medical equipment provider's stock valued at $4,675,000 after buying an additional 7,457 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on HOLX shares. Stephens restated an "overweight" rating and set a $84.00 price target on shares of Hologic in a report on Thursday, February 6th. Royal Bank of Canada lowered their price objective on Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a research note on Thursday, February 6th. Evercore ISI lowered their price objective on Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research note on Thursday, February 6th. Citigroup lowered their price objective on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Finally, Raymond James reaffirmed an "outperform" rating and issued a $90.00 price objective (down from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $84.62.

Hologic Stock Performance

Shares of Hologic stock traded up $0.28 during midday trading on Tuesday, hitting $58.36. The company had a trading volume of 1,552,009 shares, compared to its average volume of 1,971,891. Hologic, Inc. has a 12-month low of $55.89 and a 12-month high of $84.67. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The stock has a market cap of $13.10 billion, a price-to-earnings ratio of 18.41, a PEG ratio of 2.14 and a beta of 0.82. The company has a fifty day simple moving average of $60.78 and a 200 day simple moving average of $69.69.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.